health

February 20, 2026

UK clinical trial into puberty blockers paused after medicines regulator raises concerns

Study set to delay recruitment after warning participants should be a minimum of 14 years old

UK clinical trial into puberty blockers paused after medicines regulator raises concerns

TL;DR

  • The Pathways clinical trial on puberty blockers for children has been paused.
  • The MHRA has warned of "unquantified risk" of "long-term biological harms" and recommended a minimum age of 14.
  • Discussions are set to take place between the MHRA and the trial sponsor, King's College London.
  • Recruitment for the trial will not begin until the wellbeing concerns are resolved.
  • The trial was recommended following the Cass review, which found the evidence for puberty blockers' benefits to be "poor" and "weak".
  • The DHSC stated the trial will only proceed if expert evidence concludes it is safe and necessary.

Continue reading the original article

Made withNostr